bluebird bio loses 38% of value on AML scare impacting Zynteglo

17 February 2021

US biotech bluebird bio (Nasdaq: BLUE) closed 38% lower after Tuesday’s trading.

The Boston-based firm announced that it had placed its Phase I/II and Phase III studies of LentiGlobin gene therapy for sickle cell disease (SCD) on a temporary suspension due to a reported suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML).

In line with the clinical study protocols for the trial, bluebird bio placed the studies on temporary suspension following a report received last week that a patient who was treated more than five years ago in the Phase I/II study was diagnosed with AML.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK